- Investing Ideas
- U.S. Pharmaceuticals & Biotech Breakout Stocks
U.S. Pharmaceuticals & Biotech Breakout Stocks
Results
17
Stocks where the price continues to rise after more than a year of consistent gains.
17 companies
Nuvalent
Market Cap: US$9.7b
A clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
NUVL
US$123.25
7D
35.5%
1Y
57.5%
TG Therapeutics
Market Cap: US$7.0b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$49.52
7D
23.3%
1Y
37.5%
Tango Therapeutics
Market Cap: US$4.5b
A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
TNGX
US$30.94
7D
53.0%
1Y
559.7%
Enliven Therapeutics
Market Cap: US$2.8b
A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
ELVN
US$46.13
7D
32.9%
1Y
110.5%
Precigen
Market Cap: US$1.6b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.45
7D
24.3%
1Y
192.8%
ACC Aviation Holdings
Market Cap: US$643.6m
Engages in the development of cannabis powder products.
CAVG
US$1.29
7D
72.0%
1Y
1,190.0%
VERAXA Biotech
Market Cap: US$504.3m
Develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment.
VRXA
US$20.00
7D
88.7%
1Y
92.8%
Kazia Therapeutics
Market Cap: US$163.2m
Operates as an oncology-focused biotechnology company in Israel.
KZIA
US$14.28
7D
29.9%
1Y
53.5%
Rafael Holdings
Market Cap: US$116.5m
Primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
RFL
US$2.24
7D
44.5%
1Y
8.2%
Scilex Holding
Market Cap: US$59.8m
Focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
SCLX
US$8.50
7D
21.4%
1Y
76.3%
Eloxx Pharmaceuticals
Market Cap: US$54.6m
A clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia.
ELOX
US$13.52
7D
118.1%
1Y
1,230,109.3%
Breakthrough Chemistry
Market Cap: US$3.3m
Develops compounds and formulations that defy the norms prevalent in chemical industries.
BKTH
US$0.34
7D
30.6%
1Y
88.9%
American Green
Market Cap: US$1.3m
Operates as a technology company in the medical cannabis industry in the United States.
ERBB
US$0.0003
7D
50.0%
1Y
0%
Mushrooms
Market Cap: US$809.0k
Mushrooms Inc. intends to acquire and merge with small, mid-size, and development stage companies focused on the mushroom industry.
MSRM
US$0.018
7D
23.8%
1Y
38.5%
Cannabis Strategic Ventures
Market Cap: US$523.0k
Engages in the cultivation of marijuana products in the United States.
NUGS
US$0.0013
7D
30.0%
1Y
129,900.0%
MabCure
Market Cap: US$234.3k
A development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer.
MBCI
US$0.0003
7D
200.0%
1Y
200.0%
PaxMedica
Market Cap: US$88.4k
A clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms.
PXMD
US$0.0007
7D
40.0%
1Y
600.0%